Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Rhea-AI Summary
Viatris (Nasdaq: VTRS) will report fourth quarter and full year 2025 financial results on February 26, 2026 and will host a live webcast at 8:30 a.m. ET the same day. A replay will be available on the investor website.
Viatris also will host an Investor Event in New York City on March 19, 2026; additional details and pre-registration information will be provided during the February 26 investor call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VTRS declined NaN%, reflecting a moderate negative market reaction. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VTRS gained 4.51% while key peers showed smaller, mixed moves (e.g., TEVA up 2.03%, NBIX up 1.42%, ELAN down 1.81%). Momentum scanner only flagged RDY moving down, suggesting today’s move is stock-specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Risk framework launch | Positive | -2.4% | Launch of data-driven Resilience Quotient risk and resilience analytics platform. |
| Jan 08 | Leadership appointment | Positive | +1.1% | Appointment of new Chief People and Corporate Affairs Officer to align people and affairs. |
| Dec 18 | Pipeline milestones | Positive | +2.0% | Multiple FDA and PMDA regulatory milestones across generics, women’s health, and gene therapy. |
| Dec 17 | Conference presentation | Positive | +2.1% | Participation in J.P. Morgan Healthcare Conference with webcasted presentation and fireside chat. |
| Nov 24 | Investor conferences | Neutral | +1.1% | Planned participation in two December healthcare investor conferences with webcast access. |
Recent company news has generally seen modest positive price reactions, with only one notable divergence on an external risk-related announcement.
Over the last several months, Viatris has reported a series of operational and investor-related updates. Regulatory pipeline milestones on Dec 18, 2025 and conference participation on Dec 17, 2025 and Nov 24, 2025 all coincided with ~1–2% gains. A leadership appointment on Jan 8, 2026 also saw a modest positive reaction. The lone negative move followed an external risk-and-resilience announcement on Jan 15, 2026. Today’s earnings-date and investor event notice fits into this pattern of scheduled, investor-focused communications.
Market Pulse Summary
This announcement schedules Viatris’ fourth quarter and full year 2025 results for February 26, 2026, with an earnings call at 8:30 a.m. ET and a separate Investor Event on March 19, 2026. Historically, company communications such as pipeline updates and conference appearances have been followed by modest price gains. Investors may focus on how upcoming results relate to prior SEC filings, including revenue trends, net income, and cash flow discussed in the Q3 2025 Form 10-Q.
AI-generated analysis. Not financial advice.
Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.
In addition, Viatris will host an Investor Event on March 19, 2026, in
Analysts and institutional investors will be invited to pre-register for the event and attend through an invite that will be distributed separately. Interested parties will also be able to access a live webcast of the event at investor.viatris.com. A replay of the webcast also will be available on the website.
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-and-host-investor-event-on-march-19-2026-302678203.html
SOURCE Viatris Inc.
FAQ
When will Viatris (VTRS) report its Q4 and full year 2025 results?
How can investors listen to the Viatris (VTRS) earnings webcast on February 26, 2026?
What details are available about the Viatris (VTRS) Investor Event on March 19, 2026?
Will there be a replay of the Viatris (VTRS) earnings webcast if I miss the live call?
How can analysts and institutional investors attend the Viatris (VTRS) March 19, 2026 event?
